Celgene Corporation (NASDAQ:CELG) decreased 8.17% to close at $55.64. CELG traded 22.21 million shares for the day and its earning per share remained $1.98. Celgene Corporation is an integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company�s commercial stage products include REVLIMID, THALOMID (inclusive of Thalidomide Celgene and Thalidomide Pharmion, subsequent to the acquisition of Pharmion Corporation, or Pharmion), VIDAZA and FOCALIN. FOCALIN is sold exclusively to Novartis Pharma AG, or Novartis.
Gilead Sciences, Inc. (NASDAQ:GILD) decreased 1.45% to close at $36.71. GILD traded 6.94 million shares for the day and its earning per share remained $3.42. Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops and commercializes therapeutics. The Company has operations in North America, Europe and Australia. The Company sells and distributes Truvada, Viread, Emtriva, Hepsera and AmBisome in Asia, Australia, Europe, Latin America, the Middle East and New Zealand, through its commercial teams, third party distributors or partners.On April 17, 2009, Gilead acquired CV Therapeutics, Inc.
Mylan Inc. (NASDAQ:MYL) increased 1.31% to close at $20.16. MYL traded 6.62 million shares for the day and its earning per share remained $0.72. Mylan Inc. (Mylan) is a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic and branded generic pharmaceuticals, specialty pharmaceuticals and active pharmaceutical ingredients (APIs). It operates through two business segments: Generics and Specialty. During the year ended December 31, 2009, the Company acquired approximately 25% of the remaining interest in Matrix Laboratories Limited, bringing both its total ownership and control to over 96%.
No comments:
Post a Comment